



# Notice of Q3 Results

June 5, 2023

RNS Number : 5700B

Renalytix PLC

05 June 2023

## Renalytix plc ("Renalytix" or the "Company")

### Renalytix to Report Third Quarter Fiscal Year 2023 Financial Results on June 9

**LONDON and SALT LAKE CITY, June 5, 2023** -- Renalytix plc (NASDAQ: RNLX) (LSE: RENX) will report its third quarter fiscal year 2023 financial results on Friday, June 9, 2023, before market open. The Company will host a corresponding conference call and live webcast to discuss the financial results and key topics including business strategy, partnerships and regulatory and reimbursement processes, at 8:30 a.m. (ET) / 1:30 p.m. (BST).

#### Conference Call Details:

To participate in the live conference call via telephone, please register [here](#). Upon registering, a dial-in number and unique PIN will be provided in order for interested parties to join the conference call.

Webcast Registration link: <https://edge.media-server.com/mmc/p/u32tnka9>

#### *For further information, please contact:*

##### Renalytix plc

James McCullough, CEO

[www.renalytix.com](http://www.renalytix.com)

Via Walbrook PR

##### Stifel (Nominated Adviser, Joint Broker)

Alex Price / Nicholas Moore / Nick Harland / Samira Essebiyea

Tel: 020 7710 7600

##### Investec Bank plc (Joint Broker)

Gary Clarence / Shalin Bhamra

Tel: 020 7597 4000

##### Walbrook PR Limited

Paul McManus / Lianne Applegarth

Tel: 020 7933 8780 or [renalytix@walbrookpr.com](mailto:renalytix@walbrookpr.com)

Mob: 07980 541 893 / 07584 391 303

##### CapComm Partners

Peter DeNardo

Tel: 415-389-6400 or [investors@renalytix.com](mailto:investors@renalytix.com)

#### About Renalytix

Renalytix (NASDAQ: RNLX) (LSE: RENX) is an in-vitro diagnostics and laboratory services company that is the global founder and leader in the new field of bioprognosis™ for kidney health. The leadership team, with a combined 200+ years of healthcare and in-vitro diagnostic experience, has designed its KidneyIntelX laboratory developed test to enable risk assessment for rapid progressive decline in kidney function in adult patients with T2D and early CKD (stages 1-3). We believe that by understanding how disease will progress, patients and providers can take action early to improve outcomes and reduce overall health system costs. For more information, visit [www.renalytix.com](http://www.renalytix.com).

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [rns@lseg.com](mailto:rns@lseg.com) or visit [www.rns.com](http://www.rns.com).

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our [Privacy Policy](#).

END

NORSSSFDEDESEFM